Abstract
Central Centrifugal Cicatricial Alopecia (CCCA) is a form of scarring hair loss that can permanently damage hair follicles. Topical metformin 10% cream is being investigated for its potential influence on fibrosis, a process involved in scalp scarring. Across three published clinical reports involving six women, researchers described improvements in hair density or regrowth compared with baseline scalp conditions following the initiation of topical metformin. Improvements were observed over approximately four to ten months, although several patients continued other scalp medications, and the reports did not include separate control groups. Healing Dose Compounding Pharmacy works with dermatology prescribers to prepare patient-specific topical formulations based on individual prescription requirements.
When Central Centrifugal Cicatricial Alopecia (CCCA) persists to cause hair thinning despite prescribed scalp medications, patients and dermatologists may wonder what other approaches exist. One formulation drawing interest is topical metformin 10% cream, applied directly to the scalp. Case reports describe its use in patients with persistent CCCA and the changes in hair growth observed over several months.
What Is CCCA and Why Is Topical Metformin Being Studied?
CCCA typically begins with thinning at the crown and gradually spreads outward, a pattern described in 2018 research on the condition. Some patients experience itching, tenderness, or burning, while others have no symptoms. Early evaluation matters because scarring can permanently damage hair follicles.
According to the American Academy of Dermatology, dermatologists commonly prescribe corticosteroids to reduce inflammation and may add minoxidil to support hair growth.
Metformin is commonly taken by mouth for type 2 diabetes. Researchers are investigating whether applying it to the scalp could influence processes involved in scarring. One pathway of interest is AMP-activated protein kinase (AMPK), which helps regulate cellular activity.
A 2018 scalp-biopsy study identified changes in genes linked to fibrosis (scar formation) and AMPK-related signaling in CCCA tissue. These findings help explain interest in topical metformin, although the study did not directly evaluate the cream.
What Does the Clinical Evidence Show About Topical Metformin for CCCA?
Early clinical reports have examined topical metformin 10% cream in six women with central centrifugal cicatricial alopecia (CCCA), many of whom had experienced limited improvement with previously prescribed medications.
Published Clinical Findings: Baseline vs. Follow-Up
| Study | Baseline / Previous Treatment Response | Outcomes Following Topical Metformin |
|---|---|---|
| Araoye et al. (2020), Patient 1 | Minimal improvement after five years of prior therapies, including minoxidil and corticosteroid injections | Substantial hair regrowth after six months of topical metformin 10% cream |
| Araoye et al. (2020), Patient 2 | Marginal improvement after nine months of conventional scalp medications | Visible hair regrowth after four months of adding topical metformin to ongoing treatment |
| Granja et al. (2025), one patient | Persistent CCCA-related hair loss despite previous topical medications | Substantial regrowth after eight months using topical metformin 10% cream alongside minoxidil 5% lotion |
| Williams et al. (2025), three patients | Persistent hair loss or limited improvement with previously prescribed therapies | Increased hair density or regrowth observed after approximately six to ten months of treatment regimens incorporating topical metformin |
Published evidence includes six adult women across three clinical reports, many with persistent CCCA despite previous therapies.
- 2020 case report: Two women experienced visible regrowth after starting metformin 10% cream. One stopped minoxidil and steroid injections and showed regrowth at six months. The other continued those medications and showed regrowth at four months.
- 2025 case report: A 54-year-old woman experienced substantial regrowth after eight months. She applied metformin 10% cream once daily and separate minoxidil 5% lotion twice daily.
- 2025 case series: Three women with recalcitrant CCCA experienced increased hair density or regrowth after six to ten months. One used a cream combining metformin 10% and minoxidil 5%. The others used metformin alongside separate scalp medications.
The published cases document changes in hair density and regrowth compared with patients’ baseline scalp conditions. Some patients used metformin alone after discontinuing certain medications, while others continued additional therapies.
What Do These Results Suggest?
The clinical reports describe encouraging changes in hair density and regrowth compared with patients’ baseline conditions, particularly among individuals whose CCCA had shown limited response to previous therapies.
In the 2020 report, one patient experienced substantial regrowth after six months of topical metformin use following the discontinuation of minoxidil and corticosteroid injections. Another patient demonstrated improvement after four months while continuing additional scalp medications.
The 2025 reports documented similar observations, with increased hair density or visible regrowth after approximately six to ten months. However, several patients also received minoxidil, corticosteroids, or other scalp medications, making it difficult to determine how much of the improvement could be attributed specifically to metformin.
Importantly, none of these clinical reports included a separate placebo or untreated control group. The results reflect changes observed over time rather than demonstrated superiority over standard therapies.
Although these early findings support further investigation of topical metformin for CCCA, larger randomized controlled trials are needed to establish its effectiveness, optimal concentration, and application schedule.
Topical Metformin 10% Cream: Formulation and Application
The published reports provide useful details for dermatologists evaluating compounded topical metformin.
| Formulation Parameter | Published Details |
|---|---|
| Metformin concentration | 10% |
| Dosage form | Compounded topical cream |
| Vehicle | Lipoderm cream base specified in the 2020 report |
| Application frequency | Initially three times weekly, then daily in one case; daily or nightly in others |
| Combination | Metformin 10% with minoxidil 5% in one compounded preparation |
| Local tolerability | Scalp dryness and irritation reported in the 2020 cases |
Because the published cases used different application schedules and medication combinations, the dermatologist and compounding pharmacist should review the patient’s current scalp medications, proposed cream base, and application instructions when planning an individualized formulation.
What Should Patients Know About Using and Storing the Cream?
Patients should follow their prescription label and the pharmacist’s instructions because compounded formulations may differ.
- Application: Part the hair to expose the prescribed scalp area. Apply the directed amount, avoid the eyes, and wash hands afterward.
- Frequency: Follow the prescribed schedule rather than adjusting application frequency based on published cases.
- Other scalp medications: Ask the pharmacist whether separately prescribed products require different application times.
- Scalp tolerability: Dryness and irritation were reported in the original cases and improved with moisturizers or emollients. Report persistent or worsening irritation.
- Storage: Keep the container closed, follow labeled storage conditions and the beyond-use date, and keep the medication away from children.
Patients should discuss changes in hair density, scalp symptoms, and ongoing medication use with their dermatologist during follow-up.
Patient-Specific Topical Metformin Compounding at Healing Dose
Healing Dose Compounding Pharmacy works with dermatology prescribers to prepare topical metformin formulations based on each patient’s prescription and scalp medication needs.Â
Through our dermatology compounding services, pharmacists can assist with:
- Strength and dosage form: Reviewing the requested metformin concentration and cream preparation.
- Vehicle selection: Considering spreadability, scalp application, and ingredient requirements.
- Combination formulations: Assessing feasibility and compatibility when metformin is prescribed with another ingredient, such as minoxidil.
- Prescription instructions: Coordinating quantity, application area, frequency, packaging, and dispensing directions.
Based in Farmington Hills, Healing Dose works with prescribers and patients in Detroit, Novi, Southfield, and nearby Michigan communities.Â
Dermatologists can contact our pharmacy to discuss metformin 10% cream availability, formulation options, prescription requirements, and dispensing. Patients can ask their dermatologist whether the published CCCA findings apply to their individual care.
Important Compounding Disclaimer
Topical metformin compounded for CCCA-related hair loss is not FDA-approved for this indication. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality before marketing. Published evidence remains limited to small clinical reports, and use should be based on the prescriber’s independent clinical judgment, applicable compounding requirements, and the individual patient’s needs.
References:
Aguh, C., Dina, Y., Talbot, C. C., Jr., & Garza, L. (2018). Fibroproliferative genes are preferentially expressed in central centrifugal cicatricial alopecia. Journal of the American Academy of Dermatology, 79(5), 904–912.e1. Study
American Academy of Dermatology Association. (2022, March 14). Hair loss types: Central centrifugal cicatricial alopecia treatment. Link
Araoye, E. F., Thomas, J. A. L., & Aguh, C. U. (2020). Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Reports, 6(2), 106–108. Study
Granja, B. V., De Matos, P. R., Rosa, G. P., Pinheiro, J., Azevedo, F., & Pedrosa, A. F. (2025). Treatment of central centrifugal cicatricial alopecia with topical metformin 10% cream: Case report and literature review. International Journal of Dermatology, 64(1), 213–215. Study
Miteva, M. (2021). Central Centrifugal Cicatricial Alopecia (CCCA). In Hair pathology with trichoscopic correlations (pp. 123-129). CRC Press. Link
Williams, M. N., Campbell, J. R., Thakker, S., & Chheda, M. (2025). Adjuvant use of topical metformin with standard therapies in recalcitrant central centrifugal cicatricial alopecia: A case series. JAAD Case Reports, 57, 74–77. Study
